最新糖心Vlog

The development of tyrosine kinases inhibitors (TKIs) as a treatment dramatically increased survival rates, but for many patients caused debilitating side effects while losing efficacy over time. Ensuing decades of diligent research saw next-generation TKIs developed to deliver longer-lasting impact and less side effects, but still patients faced lifelong management of the disease.

By 2006, work led by Dr Pagani鈥檚 Adelaide-based colleagues A/Prof David Ross and Prof Tim Hughes, in collaboration with international teams, showed that it was possible for patients who had excellent responses to treatment to simply stop taking their medication and remain in remission. For those people who could sustain it, TFR is effectively a cure, but there was still no way to tell who would be successful and who would relapse and need to restart therapy.
听

"With this discovery, we move the conversation for people with CML from one of lifelong disease control to one of cure." Dr Ilaria Pagani, Researcher, SAHMRI and 最新糖心Vlog of Adelaide.

Today鈥檚 findings are significant because they challenge an existing assumption that response to TKI therapy is best assessed by measuring the presence of the leukaemia-defining BCR::ABL1 fusion gene in the blood of a CML patient.

鈥淯ntil now, the assumption was that every blood cell that contained BCR::ABL1 was evidence of persistent disease that could lead to relapse,鈥� Dr Pagani said.

鈥淲hat we have now shown is that the chances of relapse depend greatly on which type of cell the disease is detected in 鈥� if it鈥檚 in what are known as myeloid cells, then the chances of TFR are sadly pretty low, but if it鈥檚 in lymphocytes then that has limited impact on relapse likelihood.鈥�

This research involved a broad collaboration between Dr Pagani鈥檚 SAHMRI-based team, the 最新糖心Vlog of Adelaide, the 最新糖心Vlog of South 最新糖心Vlog, Flinders 最新糖心Vlog, SA Health and Perth-based researchers. It has been funded in part by the Leukaemia Foundation and the Cancer Council SA Beat Cancer Project.

The material outcome is a blood test that more accurately determines the best course of treatment, giving TFR candidates greater confidence before ceasing treatment.

鈥淭his new lineage-specific BCR:ABL1 test can now be used to determine who can safely stop therapy, who should continue therapy for a longer period, and who needs a different therapy before they could be considered for TFR,鈥� Dr Pagani said.

鈥淪adly, not everyone will be a candidate for TFR with current approaches, but for those whose chance of relapse is high, we will now have greater information with which to design new therapeutic approaches that can lead to TFR even for these more challenging patients.

"Ultimately, our aim is to design a curative approach for all CML patients so that TFR becomes the mainstream pathway, rather than a pathway followed by a lucky minority."

CML is a relatively rare leukaemia in terms of diagnosis, but the success of researchers and clinicians to improve survival rates mean it is an increasingly common for people to be living with the condition.

CML causes the bone marrow to produce too many white blood cells which can adversely affect normal blood cell production. In time, a shortage of blood cells can present as infection, anaemia, or unexplained bleeding or bruising. People with CML might also experience discomfort beneath their ribs on the left-hand side of their body due to an enlarged spleen.

听